MAPT and Alzheimer disease: (3) Other biomarkers: Aβ1–40, Aβ1–42, total tau (t-tau), and phosphorylated tau (p-tau) proteins in the cerebrospinal fluid (CSF) are currently the best biomarkers for clinical research and the monitoring of AD.